Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: Results of the IMAC (intervention in myocarditis and acute cardiomyopathy)-2 study

Dennis M. McNamara, Randall C. Starling, Leslie T Jr. Cooper, John P. Boehmer, Paul J. Mather, Karen M. Janosko, John Gorcsan, Kevin E. Kip, G. William Dec

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Objectives: We sought to determine clinical and demographic predictors of recovery of left ventricular function for subjects with recent onset cardiomyopathy (ROCM). Background: Although ROCM is a frequent reason for consultation and transplantation referral, its prognosis and natural history on contemporary therapy are unknown. Methods: In the multicenter IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, subjects with a left ventricular ejection fraction (LVEF) of ≤0.40, fewer than 6 months of symptom duration, and an evaluation consistent with idiopathic dilated cardiomyopathy or myocarditis were enrolled. LVEF was reassessed at 6 months, and subjects were followed up for 4 years. LVEF and event-free survival were compared by race, sex, and clinical phenotype. Results: The cohort of 373 persons was 38% female and 21% black, with a mean age of 45 ± 14 years. At entry, 91% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving beta-blockers, which increased to 92% and 94% at 6 months. LVEF was 0.24 ± 0.08 at entry and 0.40 ± 0.12 at 6 months (mean increase: 17 ± 13 ejection fraction units). Transplant-free survival at 1, 2, and 4 years was 94%, 92%, and 88%, respectively; survival free of heart failure hospitalization was 88%, 82%, and 78%, respectively. In analyses adjusted for sex, baseline LVEF, and blood pressure, LVEF at 6 months was significantly lower in blacks than in nonblacks (p = 0.02). Left ventricular end-diastolic diameter at presentation was the strongest predictor of LVEF at 6 months (p < 0.0001). Conclusions: Outcomes in ROCM are favorable but differ by race. Left ventricular end-diastolic diameter by transthoracic echo at presentation was most predictive of subsequent myocardial recovery. (Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy; NCT00575211)

Original languageEnglish (US)
Pages (from-to)1112-1118
Number of pages7
JournalJournal of the American College of Cardiology
Volume58
Issue number11
DOIs
StatePublished - Sep 6 2011

Fingerprint

Myocarditis
Dilated Cardiomyopathy
Cardiomyopathies
Stroke Volume
Demography
Symptom Assessment
Survival
Angiotensin Receptor Antagonists
Natural History
Left Ventricular Function
Angiotensin-Converting Enzyme Inhibitors
Disease-Free Survival
Hospitalization
Referral and Consultation
Heart Failure
Transplantation
Blood Pressure
Transplants
Phenotype

Keywords

  • cardiomyopathy
  • echocardiography
  • myocardial function
  • outcomes
  • recovery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy : Results of the IMAC (intervention in myocarditis and acute cardiomyopathy)-2 study. / McNamara, Dennis M.; Starling, Randall C.; Cooper, Leslie T Jr.; Boehmer, John P.; Mather, Paul J.; Janosko, Karen M.; Gorcsan, John; Kip, Kevin E.; Dec, G. William.

In: Journal of the American College of Cardiology, Vol. 58, No. 11, 06.09.2011, p. 1112-1118.

Research output: Contribution to journalArticle

McNamara, Dennis M. ; Starling, Randall C. ; Cooper, Leslie T Jr. ; Boehmer, John P. ; Mather, Paul J. ; Janosko, Karen M. ; Gorcsan, John ; Kip, Kevin E. ; Dec, G. William. / Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy : Results of the IMAC (intervention in myocarditis and acute cardiomyopathy)-2 study. In: Journal of the American College of Cardiology. 2011 ; Vol. 58, No. 11. pp. 1112-1118.
@article{385d26ee456a43eebb14e3dcd676e61f,
title = "Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: Results of the IMAC (intervention in myocarditis and acute cardiomyopathy)-2 study",
abstract = "Objectives: We sought to determine clinical and demographic predictors of recovery of left ventricular function for subjects with recent onset cardiomyopathy (ROCM). Background: Although ROCM is a frequent reason for consultation and transplantation referral, its prognosis and natural history on contemporary therapy are unknown. Methods: In the multicenter IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, subjects with a left ventricular ejection fraction (LVEF) of ≤0.40, fewer than 6 months of symptom duration, and an evaluation consistent with idiopathic dilated cardiomyopathy or myocarditis were enrolled. LVEF was reassessed at 6 months, and subjects were followed up for 4 years. LVEF and event-free survival were compared by race, sex, and clinical phenotype. Results: The cohort of 373 persons was 38{\%} female and 21{\%} black, with a mean age of 45 ± 14 years. At entry, 91{\%} were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82{\%} were receiving beta-blockers, which increased to 92{\%} and 94{\%} at 6 months. LVEF was 0.24 ± 0.08 at entry and 0.40 ± 0.12 at 6 months (mean increase: 17 ± 13 ejection fraction units). Transplant-free survival at 1, 2, and 4 years was 94{\%}, 92{\%}, and 88{\%}, respectively; survival free of heart failure hospitalization was 88{\%}, 82{\%}, and 78{\%}, respectively. In analyses adjusted for sex, baseline LVEF, and blood pressure, LVEF at 6 months was significantly lower in blacks than in nonblacks (p = 0.02). Left ventricular end-diastolic diameter at presentation was the strongest predictor of LVEF at 6 months (p < 0.0001). Conclusions: Outcomes in ROCM are favorable but differ by race. Left ventricular end-diastolic diameter by transthoracic echo at presentation was most predictive of subsequent myocardial recovery. (Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy; NCT00575211)",
keywords = "cardiomyopathy, echocardiography, myocardial function, outcomes, recovery",
author = "McNamara, {Dennis M.} and Starling, {Randall C.} and Cooper, {Leslie T Jr.} and Boehmer, {John P.} and Mather, {Paul J.} and Janosko, {Karen M.} and John Gorcsan and Kip, {Kevin E.} and Dec, {G. William}",
year = "2011",
month = "9",
day = "6",
doi = "10.1016/j.jacc.2011.05.033",
language = "English (US)",
volume = "58",
pages = "1112--1118",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy

T2 - Results of the IMAC (intervention in myocarditis and acute cardiomyopathy)-2 study

AU - McNamara, Dennis M.

AU - Starling, Randall C.

AU - Cooper, Leslie T Jr.

AU - Boehmer, John P.

AU - Mather, Paul J.

AU - Janosko, Karen M.

AU - Gorcsan, John

AU - Kip, Kevin E.

AU - Dec, G. William

PY - 2011/9/6

Y1 - 2011/9/6

N2 - Objectives: We sought to determine clinical and demographic predictors of recovery of left ventricular function for subjects with recent onset cardiomyopathy (ROCM). Background: Although ROCM is a frequent reason for consultation and transplantation referral, its prognosis and natural history on contemporary therapy are unknown. Methods: In the multicenter IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, subjects with a left ventricular ejection fraction (LVEF) of ≤0.40, fewer than 6 months of symptom duration, and an evaluation consistent with idiopathic dilated cardiomyopathy or myocarditis were enrolled. LVEF was reassessed at 6 months, and subjects were followed up for 4 years. LVEF and event-free survival were compared by race, sex, and clinical phenotype. Results: The cohort of 373 persons was 38% female and 21% black, with a mean age of 45 ± 14 years. At entry, 91% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving beta-blockers, which increased to 92% and 94% at 6 months. LVEF was 0.24 ± 0.08 at entry and 0.40 ± 0.12 at 6 months (mean increase: 17 ± 13 ejection fraction units). Transplant-free survival at 1, 2, and 4 years was 94%, 92%, and 88%, respectively; survival free of heart failure hospitalization was 88%, 82%, and 78%, respectively. In analyses adjusted for sex, baseline LVEF, and blood pressure, LVEF at 6 months was significantly lower in blacks than in nonblacks (p = 0.02). Left ventricular end-diastolic diameter at presentation was the strongest predictor of LVEF at 6 months (p < 0.0001). Conclusions: Outcomes in ROCM are favorable but differ by race. Left ventricular end-diastolic diameter by transthoracic echo at presentation was most predictive of subsequent myocardial recovery. (Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy; NCT00575211)

AB - Objectives: We sought to determine clinical and demographic predictors of recovery of left ventricular function for subjects with recent onset cardiomyopathy (ROCM). Background: Although ROCM is a frequent reason for consultation and transplantation referral, its prognosis and natural history on contemporary therapy are unknown. Methods: In the multicenter IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, subjects with a left ventricular ejection fraction (LVEF) of ≤0.40, fewer than 6 months of symptom duration, and an evaluation consistent with idiopathic dilated cardiomyopathy or myocarditis were enrolled. LVEF was reassessed at 6 months, and subjects were followed up for 4 years. LVEF and event-free survival were compared by race, sex, and clinical phenotype. Results: The cohort of 373 persons was 38% female and 21% black, with a mean age of 45 ± 14 years. At entry, 91% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving beta-blockers, which increased to 92% and 94% at 6 months. LVEF was 0.24 ± 0.08 at entry and 0.40 ± 0.12 at 6 months (mean increase: 17 ± 13 ejection fraction units). Transplant-free survival at 1, 2, and 4 years was 94%, 92%, and 88%, respectively; survival free of heart failure hospitalization was 88%, 82%, and 78%, respectively. In analyses adjusted for sex, baseline LVEF, and blood pressure, LVEF at 6 months was significantly lower in blacks than in nonblacks (p = 0.02). Left ventricular end-diastolic diameter at presentation was the strongest predictor of LVEF at 6 months (p < 0.0001). Conclusions: Outcomes in ROCM are favorable but differ by race. Left ventricular end-diastolic diameter by transthoracic echo at presentation was most predictive of subsequent myocardial recovery. (Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy; NCT00575211)

KW - cardiomyopathy

KW - echocardiography

KW - myocardial function

KW - outcomes

KW - recovery

UR - http://www.scopus.com/inward/record.url?scp=80052390541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052390541&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2011.05.033

DO - 10.1016/j.jacc.2011.05.033

M3 - Article

C2 - 21884947

AN - SCOPUS:80052390541

VL - 58

SP - 1112

EP - 1118

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 11

ER -